Loading stock research
Loading stock research…
No token price observed
Observation time unavailableUnavailable
Daily closes of KVUE, the underlying share. A token’s rights, price and liquidity can differ from the share.
Research observed · Source: Yahoo Finance, Wikipedia (CC BY-SA)
The company behind KVUE.
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey. Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index.
What you would hold, where it trades and where these numbers come from.
Observation time unavailableUnavailable
Observed · Source: Company profile
Momentum from daily closes of the underlying share.
Computed from daily closes of the underlying share, not the token. Not a recommendation.
Close of · Source: Yahoo Finance daily closesStale
Reported financials. They describe the company, not the token’s market value.
| Item | Period end | Value |
|---|---|---|
| Revenue (annual) | 31 Dec 2025 | $15.12B |
| Revenue (annual) | 31 Dec 2024 | $15.46B |
| Revenue (annual) | 31 Dec 2023 | $15.44B |
| Revenue (annual) | 31 Dec 2022 | $14.95B |
| Net income (annual) | 31 Dec 2025 | $1.47B |
| Net income (annual) | 31 Dec 2024 | $1.03B |
| Net income (annual) | 31 Dec 2023 | $1.66B |
| Net income (annual) | 31 Dec 2022 | $2.06B |
| Diluted EPS (annual) | 31 Dec 2025 | 0.76 USD/share |
| Diluted EPS (annual) | 31 Dec 2024 | 0.54 USD/share |
| Diluted EPS (annual) | 31 Dec 2023 | 0.90 USD/share |
| Diluted EPS (annual) | 31 Dec 2022 | 1.09 USD/share |
| Total assets (annual) | 31 Dec 2025 | $27.08B |
| Total assets (annual) | 31 Dec 2024 | $25.60B |
| Total assets (annual) | 31 Dec 2023 | $27.85B |
| Total assets (annual) | 31 Dec 2022 | $27.32B |
| Total debt (annual) | 31 Dec 2025 | $8.67B |
| Total debt (annual) | 31 Dec 2024 | $8.72B |
| Total debt (annual) | 31 Dec 2023 | $8.43B |
| Total debt (annual) | 31 Dec 2022 | $116.00M |
| Operating cash flow (annual) | 31 Dec 2025 | $2.20B |
| Operating cash flow (annual) | 31 Dec 2024 | $1.77B |
| Operating cash flow (annual) | 31 Dec 2023 | $3.17B |
| Operating cash flow (annual) | 31 Dec 2022 | $2.53B |
| Free cash flow (annual) | 31 Dec 2025 | $1.72B |
| Free cash flow (annual) | 31 Dec 2024 | $1.34B |
| Free cash flow (annual) | 31 Dec 2023 | $2.70B |
| Free cash flow (annual) | 31 Dec 2022 | $2.15B |
| Revenue (quarterly) | 30 Sept 2026 | $3.89B |
| Revenue (quarterly) | 30 Jun 2026 | $3.96B |
| Revenue (quarterly) | 31 Mar 2026 | $3.91B |
| Revenue (quarterly) | 31 Dec 2025 | $3.78B |
| Revenue (quarterly) | 30 Sept 2025 | $3.76B |
| Net income (quarterly) | 30 Sept 2026 | $430.00M |
| Net income (quarterly) | 30 Jun 2026 | $456.00M |
| Net income (quarterly) | 31 Mar 2026 | $474.00M |
| Net income (quarterly) | 31 Dec 2025 | $330.00M |
| Net income (quarterly) | 30 Sept 2025 | $398.00M |
| Diluted EPS (quarterly) | 30 Sept 2026 | 0.22 USD/share |
| Diluted EPS (quarterly) | 30 Jun 2026 | 0.24 USD/share |
| Diluted EPS (quarterly) | 31 Mar 2026 | 0.25 USD/share |
| Diluted EPS (quarterly) | 31 Dec 2025 | 0.17 USD/share |
| Diluted EPS (quarterly) | 30 Sept 2025 | 0.21 USD/share |
Reported dividends, splits and filings, each linked to its source.
Recent headlines about the company.
No recent news was found for this company.